Cubicin (daptomycin for injection) 500 mg in 10 mL Single Use Vials Recalled: AttorneyOne Monitors and Keeps Consumers Informed

On August 9, Cubist Pharmaceuticals, Inc. announced the recall of certain lots of Cubicin (daptomycin for injection) 500 mg due to the presence of particulate matter. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Cubicin (daptomycin for injection) 500 mg Recalled

Cubicin (daptomycin for injection) 500 mg Recalled

Our focus should squarely fall on investigating these safety alerts and getting the word out.

San Diego, CA (PRWEB) August 12, 2014

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Cubicin (daptomycin for injection).

Cubist Pharmaceuticals, Inc. announced on August 9, the recall of nine lots of Cubicin (daptomycin for injection) 500 mg in 10 mL Single Use Vials due to the presence of particulate matter. Cubicin is used intravenously to treat skin infections and certain blood stream infections.

The reason for the recall is the potential presence of glass particulate matter in vials. If administered, this product may cause a thromboembolism or a life-threatening pulmonary emboli. Moreover, it can cause activation of platelets, subsequent generation of microthrombi, phlebitis, or mechanical block of the capillaries or arterioles. Increased risk exists for patients with a preexisting condition of trauma or other medical condition that adversely affects the microvascular blood supply.

The affected lot numbers are CDC203, CDC207, CDC213, CDC217, CDC226, CDC234, CDC235, CDC243, and CDC246.

Taking into consideration the latest developments, AttorneyOne.com monitors daily and updates the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds, “we are determined to keep an eye on FDA announcements concerning Cubicin (daptomycin for injection) and inform the public. For that reason," he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”

As the FDA recommends, “Anyone with an existing inventory of the product lots listed should determine whether they have product from the recalled lots, quarantine, and discontinue distribution of these recalled lots of the product.”

AttorneyOne.com has further information on Cubicin (daptomycin for injection) at the website including latest major drug, food, and medical products law news.

Headquartered in San Diego, CA, Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/08/prweb12084845.htm.